Towa Pharmaceutical Co., Ltd. (TYO:4553)

Market Cap	166.88B
Revenue (ttm)	266.67B
Net Income (ttm)	20.65B
Shares Out	49.23M
EPS (ttm)	419.38
PE Ratio	8.08
Forward PE	9.05
Dividend	80.00 (2.40%)
Ex-Dividend Date	Mar 30, 2026

Volume	179,200
Average Volume	172,205
Open	3,385.00
Previous Close	3,340.00
Day's Range	3,365.00 - 3,450.00
52-Week Range	2,298.00 - 3,445.00
Beta	-0.33
RSI	76.15
Earnings Date	Nov 10, 2025

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 4,788
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4553

Financial Performance

In 2024, Towa Pharmaceutical's revenue was 259.59 billion, an increase of 13.89% compared to the previous year's 227.93 billion. Earnings were 18.99 billion, an increase of 17.39%.